- Division of Translational and Clinical Sciences – DTCS
- Oncology – Translational Clinical – OTC
- Study Section:
- Cancer Diagnostics and Treatments (CDT) SBIR/STTR SEP – OTC (13)
Dr. Maria Cardenas-Corona joined CSR following her retirement as a research professor emeritus of molecular genetics and microbiology at Duke University School of Medicine. During her academic career, her studies focused on the elucidation of the mechanism of action of the anti-cancer, immunosuppressive and anti-aging drug rapamycin, the dissection of its target in the mTORC1 signaling cascade, and the characterization of mTORC1 roles in cell fitness and growth control. Simultaneously, she conducted studies to elucidate the roles of the calcineurin pathway in stress responses and fungal virulence. Dr. Cardenas-Corona was a member of the Duke Cancer Institute, several Duke University graduate programs, and NIH study sections and review panels. She is an elected member of the American Association for the Advancement of Science (AAAS) for distinguish scientific contributions to the cell signaling field. She is the author of numerous publications, including review and original research articles, and book chapters.